Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 5
Author: Geojit BNP Paribas

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	12 Sep 2025	Sun Pharmaceutical	Consensus Share Price Target	1616.60	1930.16	-	19.40	buy	pdf Detailed Estimates
	31 May 2023	Sun Pharmaceutical	Geojit BNP Paribas Reco Target	1616.60	1101.00	975.35 (65.75%)	Target met	Buy	pdf post cache	Broker Report SUN PHARMA Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	30 May 2023	Sun Pharmaceutical	BOB Capital Markets Ltd. Reco Target	1616.60	1130.00	959.60 (68.47%)	Target met	Buy	pdf post cache	Broker Report Sun Pharma (BUY): gRevlimid yields margin surprise; raise to BUY post correction BOB Capital Markets Ltd. Q4 revenue in line but adj. PAT 9% above consensus at Rs 21.8bn (+46% YoY) on account of strong margins pdf Copy Link Share on Share on Share on Share on Alert
	30 May 2023	Sun Pharmaceutical	SMC online	1616.60		959.60 (68.47%)			pdf post cache	Broker Report Sun Pharmaceutical Industries SMC online pdf Copy Link Share on Share on Share on Share on Alert
	29 May 2023	Sun Pharmaceutical	Sharekhan Target	1616.60	1123.00	975.35 (65.75%)	Target met	Buy	pdf post cache	Broker Report Sun Pharma Sharekhan pdf Copy Link Share on Share on Share on Share on Alert
	28 May 2023	Sun Pharmaceutical	Prabhudas Lilladhar Target	1616.60	1140.00	969.90 (66.68%)	Target met	Buy	pdf post cache	Broker Report SUN PHARMACEUTICAL I Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	27 May 2023	Sun Pharmaceutical	ICICI Securities Limited Reco Target	1616.60	1160.00	969.90 (66.68%)	Target met	Buy	pdf post cache	Broker Report Specialty portfolio is amplifying margins ICICI Securities Limited Sun Pharmaceutical’s (Sun) Q4FY23 performance was decent, aided by traction in specialty portfolio, India branded and launch of Revlimid in the US. Specialty business sales contribution had increased to 16.6% in FY23 (14% in FY22) and key assets like Ilumya, Winlevi and Cequa will likely improve the share to 21% by FY25E. pdf Copy Link Share on Share on Share on Share on Alert
	27 May 2023	Sun Pharmaceutical	ICICI Direct Target	1616.60	1140.00	969.90 (66.68%)	Target met	Buy	pdf post cache	Broker Report Sun Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	27 May 2023	Sun Pharmaceutical	Motilal Oswal Target	1616.60	1160.00	969.90 (66.68%)	Target met	Buy	pdf post cache	Broker Report US/EM/ROW drive earnings for the quarter Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2023	Sun Pharmaceutical	ICICI Direct Target	1616.60	1210.00	1014.90 (59.29%)	Target met	Buy	pdf post cache	Broker Report Sun Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2023	Sun Pharmaceutical	ICICI Securities Limited Target	1616.60	1001.00	1034.50 (56.27%)	Target met	Hold	pdf post cache	Broker Report In-line performance; valuations fair ICICI Securities Limited Sun Pharmaceutical’s (Sun) Q3FY23 performance was largely in line with our estimates. Consolidated revenue grew 12.9% YoY to Rs111.4bn (I-Sec: Rs110.5bn) driven by US and emerging market sales. EBITDA margin stood at 26.0% (I-Sec: 26.6%). Specialty portfolio grew 10.7% QoQ to US$223mn (ex- milestone income) led by growth in Ilumya and Winlevi. pdf Copy Link Share on Share on Share on Share on Alert
more loading

Near 52W Low of ₹1553.05

Sun Pharmaceutical Industries Ltd. share price target

Sun Pharmaceutical Industries Ltd. has an average share price target of 2050.25. The consensus estimate represents an upside of 26.82% from the last price of 1616.60. View 14 reports from 8 analysts offering long-term price targets for Sun Pharmaceutical Industries Ltd..

SUN PHARMA

Sun Pharma (BUY): gRevlimid yields margin surprise; raise to BUY post correction

Sun Pharmaceutical Industries

Sun Pharma

SUN PHARMACEUTICAL I

Specialty portfolio is amplifying margins

Sun Pharma

US/EM/ROW drive earnings for the quarter

Sun Pharma

In-line performance; valuations fair

Advisor Screeners